Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | PKM | P14618 | 2/20 | 0.69 |
| ▸ | SNCA | P37840 | 2/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | CA3 | P07451 | 1/20 | 0.69 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.69 |
| ▸ | CA4 | P22748 | 1/20 | 0.69 |
| ▸ | CA6 | P23280 | 1/20 | 0.69 |
| ▸ | CA5A | P35218 | 1/20 | 0.69 |
| ▸ | CA7 | P43166 | 1/20 | 0.69 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.69 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1536425 | 1.00 | KDM4E (0.73) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL584262 | 0.87 | KDM4E (0.73) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL584263 | 0.87 | KDM4E (0.73) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL22391534 | 0.87 | APP (0.69) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL27092069 | 0.87 | APP (0.69) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL23350066 | 0.86 | BACE1 (0.64) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL13953312 | 0.86 | BACE1 (0.86) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| Hydrochloric Acid SCHEMBL6818633 | 0.86 | KDM4E (0.71) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| O,O'-Dimethylcaffeic Acid SCHEMBL81317 | 0.85 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10ALOX15 | |
| O,O'-Dimethylcaffeic Acid SCHEMBL81318 | 0.85 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-08-19 | — | — | US | disclosed |
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-08-19 | — | — | US | disclosed |
| US-20210139414-A1 | NOVEL BENZYLIDENEACETONE DERIVATIVE AND USE THEREOF | KORPHARM CO., LTD. (KR) | 2021-05-13 | — | — | US | disclosed |
| EP-3793550-A2 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2021-03-24 | — | — | EP | disclosed |
| EP-2914613-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2914613-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-9598433-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598433-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598433-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2005051410-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050113399-A1 | Substituted isoquinolinones | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050096350-A1 | Halo substituted benzo[b]thiophenes as therapeutic agents | CONNOLLY MICHAEL K (US) | 2005-05-05 | — | — | US | disclosed |
| US-20050090432-A1 | Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-28 | — | — | US | disclosed |
| WO-2005035520-A1 | SUBSTITUTED ISOQUINOLINONES | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005023800-A1 | HALO SUBSTITUTED BENZO`B! THIOPHENES WITH PI3K INHIBITORY ACTIVITY AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-1505963-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004094452-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040106559-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113399-A1 | Substituted isoquinolinones | PFKP, MPL, TBXA2R | KDM4E 4493/4885ALDH1A1 1929/4885HPGD 439/4885 |
| US-20210139414-A1 | NOVEL BENZYLIDENEACETONE DERIVATIVE AND USE THEREOF | EBP, CREBBP, BPTF | KDM4E 739/4885ALDH1A1 34/4885HPGD 192/4885 |
| US-20050096350-A1 | Halo substituted benzo[b]thiophenes as therapeutic agents | HCLS1, BRI3BP, BRPF1 | KDM4E 2444/4885ALDH1A1 1084/4885HPGD 2703/4885 |
| US-20050090432-A1 | Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus | VIP, QPCT, HCCS | KDM4E 4060/4885ALDH1A1 4253/4885HPGD 2959/4885 |
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, CDV3, HMBS | KDM4E 1113/4885ALDH1A1 3136/4885HPGD 981/4885 |
| US-20040106559-A1 | Hepatitis C virus inhibitors | HAVCR2, HCCS, RNASE1 | KDM4E 2792/4885ALDH1A1 512/4885HPGD 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.